China Pharma Univ. VDR compound 16i

China Pharma Univ. VDR compound 16i: sourced facts only. name: "In conclusion, compound 16i is a potent VDR agonist with significant anti-hepatic fibrosis action both in vitro and in vivo." [PMID:37406383]; target: "In conclusion, compound 16i is a potent VDR agonist with significant anti-hepatic fibrosis action both in vitro and in vivo." [PMID:37406383]; developer: "State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing, 211198, PR China." [PMID:37406383]; stage: "In models of CCl4-induced and bile duct ligation-induced hepatic fibrosis, compound 16i showed the most significant therapeutic effect by ultrasound imaging and histological examination." [PMID:37406383]